Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2020 | KEYNOTE-204: pembrolizumab vs brentuximab vedotin in R/R cHL

John Kuruvilla • 8 Dec 2020
ASH 2020
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Pembrolizumab
KEYNOTE-204

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, discusses the patient-reported outcomes from the Phase III KEYNOTE-204 trial (NCT02684292) of pembrolizumab versus brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (cHL) patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from John Kuruvilla

The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies 0:54
The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies
John Kuruvilla • 19 Jun 2025
Exciting advances in the lymphoma treatment landscape: BTK degraders 1:01
Exciting advances in the lymphoma treatment landscape: BTK degraders
John Kuruvilla • 19 Jun 2025
The safety of alloSCT following pembrolizumab treatment in R/R HL 1:11
The safety of alloSCT following pembrolizumab treatment in R/R HL
John Kuruvilla • 19 Jun 2025
Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals